The AFF4 Knockout HeLa Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the AFF4 gene in the HeLa cervical adenocarcinoma cell line. This resource provides a heterogeneous mixture of edited cells harboring loss-of-function mutations at the AFF4 locus, enabling robust investigation of AFF4-dependent transcriptional regulation without clonal selection biases. The polyclonal format captures the diversity of CRISPR-induced genetic alterations across the cell pool, offering a reliable model for population-level functional genomics studies that demand physiological relevance and minimized clonal artifact.
HeLa cells, derived from a cervical adenocarcinoma in 1951, are a widely employed immortalized human epithelial line that retains HPV-18 sequences and exhibits an aneuploid karyotype. Their robust proliferation, ease of manipulation, and extensive characterization make HeLa cells a standard host for dissecting oncogenic signaling and gene regulatory mechanisms. The integration of AFF4 knockout in this well-defined background provides a tractable platform for exploring how transcriptional elongation complex dynamics intersect with cancer cell biology, particularly in the context of cervix-derived adenocarcinoma and broader tumorigenic processes.
AFF4 functions as an essential scaffolding component of the super elongation complex (SEC), a master regulator of RNA polymerase II (Pol II) transcriptional elongation. Within the SEC, AFF4 directly recruits P-TEFb, comprising CDK9 and Cyclin T1, which phosphorylates the C-terminal domain of Pol II to release promoter-proximal pausing. This action licenses productive elongation of target genes such as MYC, BCL2, and HOX clusters (e.g., HOXA9, HOXA10). AFF4 interacts with multiple SEC partners including ELL2, ENL, AF9, and DOT1L, and its activity is modulated by upstream factors like hormone receptors and cellular stress signals. Notably, leukemogenic MLL-AFF4 fusion proteins aberrantly assemble SEC variants that drive sustained oncogenic transcription, highlighting the gene’s central role in both normal elongation control and malignant transformation.
In the HeLa cellular environment, which harbors intact Pol II machinery and active pro-survival pathways, disruption of AFF4 permits dissection of SEC-dependent transcriptional programs underlying cancer phenotypes. HeLa??s endogenous expression of HPV oncoproteins and altered signaling networks may intersect with AFF4-regulated elongation, offering a unique model to study how viral and cellular factors cooperate in gene dysregulation. The knockout cells enable assessment of SEC contributions to processes such as proliferation, apoptosis resistance, and migration, providing insights into the molecular dependencies of cervical adenocarcinoma and other AFF4-implicated malignancies.
These polyclonal cells suit a diverse array of research applications, including genome-wide transcriptomic profiling via RNA-seq, targeted gene expression analysis by RT-qPCR, and chromatin occupancy studies with ChIP-qPCR to map SEC localization. Protein interaction networks can be interrogated through co-immunoprecipitation and Western blotting, while functional assays such as proliferation, apoptosis, and migration analyses reveal phenotypic consequences of AFF4 loss. Additionally, the model supports drug screening efforts aimed at inhibiting SEC function, with readouts from flow cytometry contributing to compound evaluation. For further details on experimental implementation, please contact Ascent Research.
